Barclays PLC Tarsus Pharmaceuticals, Inc. Transaction History

Barclays PLC

$377 Billion
Q3 2024

A detailed history of Barclays PLC transactions in Tarsus Pharmaceuticals, Inc. stock. As of the latest transaction made, Barclays PLC holds 98,663 shares of TARS stock, worth $4.84 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

98,663

Previous 98,663 -0.0%

Holding current value

$4.84 Million

Previous $3.25 Million -0.0%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 15, 2024	BUY	$21.54 - $34.6 $1.65 Million - $2.65 Million	76,538 Added 345.93%	98,663 $3.25 Million
Q2 2024 Aug 14, 2024	SELL	$25.17 - $38.73 $205,966 - $316,927	-8,183 Reduced 27.0%	22,125 $600,000
Q1 2024 May 15, 2024	SELL	$19.61 - $39.22 $332,409 - $664,818	-16,951 Reduced 35.87%	30,308 $1.1 Million
Q4 2023 Feb 15, 2024	BUY	$12.98 - $20.73 $462,373 - $738,444	35,622 Added 306.11%	47,259 $957,000
Q3 2023 Nov 07, 2023	SELL	$14.75 - $24.62 $48,955 - $81,713	-3,319 Reduced 22.19%	11,637 $206,000
Q2 2023 Aug 03, 2023	BUY	$11.57 - $19.63 $5,102 - $8,656	441 Added 3.04%	14,956 $270,000
Q1 2023 May 04, 2023	BUY	$11.92 - $16.27 $78,636 - $107,333	6,597 Added 83.32%	14,515 $183,000
Q4 2022 Feb 13, 2023	BUY	$14.12 - $18.72 $58,696 - $77,819	4,157 Added 110.53%	7,918 $116,000
Q3 2022 Nov 03, 2022	SELL	$14.08 - $18.5 $1,844 - $2,423	-131 Reduced 3.37%	3,761 $64,000
Q2 2022 Aug 12, 2022	BUY	$11.08 - $19.08 $14,392 - $24,784	1,299 Added 50.1%	3,892 $57,000
Q1 2022 May 16, 2022	BUY	$14.49 - $24.28 $37,572 - $62,958	2,593 New	2,593 $44,000

Others Institutions Holding TARS

# of Institutions

173

Shares Held

43.6M

Call Options Held

484K

Put Options Held

4.1K

View Full List

About Tarsus Pharmaceuticals, Inc.

Ticker TARS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,658,500
Market Cap $1.31B
Description
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as...

More about TARS

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

News

Stay updated on Barclays PLC with notifications on news.

Account